bluebird bio
NEWS
bluebird bio stock has been on an upswing for most of the year, having recently taken a spike after positive news at the ASH Annual Meeting.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
Celgene and bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the ASH Annual Meeting.
These great biotech stocks to buy for the holidays come in all sizes -- small-cap, mid-cap, and large-cap.
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
At 14.1%, healthcare is the third largest weighted sector in the S&P 500 index, and with 76 million baby boomers getting older and living longer, owning healthcare stocks in your portfolio makes sense.
Bluebird is making forays into the CAR-T immuno-oncology market, although it has yet to bring a product to market.
Immuno-oncology and gene therapy has been a hot field for the last few years, and the approval of the first CAR-T therapies has only set the kindling ablaze.
JOBS
IN THE PRESS
bluebird bio, Inc. (Nasdaq: BLUE) announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).
Celgene Corporation and bluebird bio, Inc. today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma. bb2121 is being developed as part of a Co-Development, Co-Promote and Profit Share Agreement between Celgene and bluebird bio.
bluebird bio (Nasdaq: BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.m. ET at the Boston Harbor Hotel, Boston.
Company plans to pursue accelerated development pathway for LentiGlobinTM in sickle cell disease (SCD)
European Medicines Agency Will Evaluate LentiGlobin Marketing Authorization Application Under Accelerated Assessment
bluebird bio, Inc. today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3, at 3:30 p.m. ET at the Lotte New York Palace, New York City.
More than 100 life sciences experts will share best practices to unify processes in clinical, regulatory, and quality
Updated Efficacy and Safety Data Consistent with Previously Reported Phase 2/3 Starbeam Results
bluebird bio, Inc. today announced that members of the management team will present at the following upcoming investor conferences:
bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.